CXCR4 mutation subtypes impact response and survival outcomes in ibrutinib-treated WM

Key Findings

• ●CXCR4 nonsense mutations associated with more aggressive presentation
• ●Lower major response rates (67% vs 86%) in CXCR4-mutated patients on ibrutinib
• ●CXCR4 mutations and low platelets predict worse PFS

Referenced in (1 disease)

1. passsource metadataJun 1, 2026, 04:40 PMby pubmed-api

   Stored DOI was incorrect; corrected to the PubMed-registered DOI (verified to resolve to this article).

   tools: pubmed.esummary, crossref.works